tcs prp inhibitor 13

TCS PrP Inhibitor 13 (5-(4-Nitrophenyl)-2-Phenyl-4H-Pyrazol-3-One) is an antiprion agent inhibiting protease-resistant prion protein (PrP-res) accumulation.

mTOR inhibitor 13 is a selective mTOR inhibitor with IC50 of 0.29nM and 119nM for mTOR and PI3Kα, respectively.

Topoisomerase II inhibitor 13 inhibits topoisomerase II (Topo II) that shows strong anti-proliferation activity against HL-60/MX2 cancer cells derived from HL-60 against Topo II toxicity.

Chitin Synthase Inhibitor 13 (compound 12g), a non-competitive antagonist of chitin synthase, demonstrates broad-spectrum antifungal activity and has an inhibition concentration (IC50) of 106.7 μM [1].

DNA Primase Inhibitor-13 is a novel inhibitor of DNA primase.

P-gp Inhibitor 13, a P-glycoprotein antagonist, can counteract paclitaxel resistance in A2780/T cells, proving valuable for advanced acute myeloid leukemia research [1].

HIV-1 inhibitor-13 is an orally active HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) with an IC50 value of 0.14 μM against HIV-1 RT. HIV-1 inhibitor-13 is active against HIV-1 resistant strains (EC50: 2.85-18.0 nM).

PI3K/mTOR Inhibitor-13, an orally active dual inhibitor targeting phosphoinositol 3-kinase (PI3K) and mTOR kinase, holds potential for treating sexual diseases, solid tumors, and idiopathic pulmonary fibrosis (IPF).

Tubulin Inhibitor 13 (E27) effectively inhibits tubulin polymerization with an IC50 of 16.1 μM. This compound also restricts cancer cell migration and invasion, promotes apoptosis, and exhibits notable anticancer activity [1].

KRAS inhibitor-13 (compound 5-6) is a potent inhibitor of KRAS G12C (IC50: 0.883 μM). KRAS inhibitor-13 has a p-ERK inhibitory effect in MIA PaCA-2, A549 cells with IC50 values of 5.9 and >100 μM respectively. KRAS inhibitor-13 has potential to be studied in pancreatic, colorectal and lung cancers.

MMP-9/MMP-13 Inhibitor I is a dual inhibitor of MMP-9 and MMP-13 with IC50 of both 0.9 nM. MMP-9/MMP-13 Inhibitor I is over 20 times more selective for MMP-9/MMP-13 than other MMPs.

ATX inhibitor 13 (compound 10c) is an orally active ATX inhibitor (IC50: 3.4 nM). ATX inhibitor 13 is capable of blocking the cell cycle of RAW264.7 cells in the G2 phase, inhibiting cell proliferation and migration and inducing apoptosis. ATX inhibitor 13 exhibited an inhibitory effect on tumour colony formation.

KRAS G12C inhibitor 13 is a KRAS G12C inhibitor .

BTK inhibitor 13 (compound 8) is an effective and selective BTK inhibitor(IC50: 1.2 nM).

KRAS G12D inhibitor 13 is a potent inhibitor of KRAS G12D. KRAS G12D inhibitor 13 has shown potential for the investigation of KRAS G12D-mediated cancers.

Carbonic anhydrase inhibitor 13 (compound 7) is a potent inhibitor of carbonic anhydrase (CA).

Mcl-1 Inhibitor 13 (Example 9), with a Ki of 8.2 nM, serves as an MCL-1 inhibitor suitable for cancer research [1].